ESI Group and the DesCartes Program Aiming at Transforming Singapore Into a Hybrid, Ethical and Sustainable Smart Nation
25.1.2022 10:00:00 EET | Business Wire | Press release
Regulatory News:
ESI Group, Rungis, France, (ISIN Code: FR0004110310, Mnemo: ESI), a global player in virtual prototyping for industries, is collaborating in the launch of the DesCartes project in Singapore by providing its scientists, its expertise in hybridization methods and its virtual prototyping software solutions to the various stakeholders.
DesCartes a 5-year and a 35 million euros budget collaborative program, has been selected by the National Research Foundation (NRF) of Singapore and is based on the CREATE campus, "Campus for research excellence and technological enterprise", the international research hub of Singapore. Behind this very French name lies one of the largest collaborative programs of the CNRS: the "Program on Intelligent Modelling for Decision-making in Critical Urban Systems", dedicated to Hybrid Artificial Intelligence.
A smart city project to a better extent: A smart nation project
For many years, many smart cities projects have been launched. The principle of these smart cities is to collect data generated by sensors, to deploy specific applications, such as sensors indicating air pollution, alerts on accidents, traffic conditions in real time... However, the concept of smart nation carried by Singapore differs from the others because it pushes the concept to its paroxysm: from the digitization of an entity, a building, a single system to the digitization of a whole city interacting in real time.
From electrical grid optimization to delivery drones
DesCartes is developing hybrid AI methods, combining AI with knowledge-based models (physics, engineering), to enable trusted, real-time decision-making that is "people-centric" and "in harmony with society." All in response to complex situations related to critical urban systems in the context of Singapore's "Smart Nation." This research will be applied, for example, to urban mobility or energy management, or to anticipate the needs of future transportation networks, smart industries, or smart buildings. "For example, we aim to develop solutions to optimize the supply and demand of the electricity network, or solutions to improve the flow of cab drones or delivery drones, or to develop intelligent predictive maintenance applied to industrial tools," explains Dominique Baillargeat, director of CNRS@CREATE. Systems in the city that will be able to analyze data on the use of services by the population and then make optimization decisions.
ESI's role in this project.
ESI, recognized worldwide for its predictive physics modeling and virtual prototyping expertise, will play several roles in this program. First, its Scientific Director, also a member of CNRS and ENSAM, Prof. Francisco Chinesta, will be the program director. In addition, the Group will make its performance simulation solutions (VPS, VA One, Simulation X, etc.) and its expertise in hybridization and model reduction methods available to the partners and the program. ESI will thus be able to predict material behavior in real time, anticipate incidents (associated with damage, cracks, corrosion, etc.), model the wind for better use of drones, and make city management more intelligent and human-friendly. Finally, ESI will bring all its engineering expertise to optimize the platform in which the data will be used to make the right decision at the right time.
Dr. Francisco Chinesta, leader of the engineering activity for ESI in this project, says: "The goal of the Singapore program is to think and design an interconnected smart city with features that will revolutionize the concept of smart cities. In this project, it is essential to place the citizen - the human, but also more generally the living - at the heart of the hybridization devices. All the partners in this project aim to make Singapore an ethical, responsible and secure new city."
The Descartes program partners
The Descartes project involves on the French side:
- CNRS
- 13 universities and prestigious schools : Université Paris-Saclay, Université Toulouse Paul Sabatier, Université Lyon III Jean Moulin, Université de Bordeaux, École Nationale de l'Aviation Civile, Université Paris Sciences & Lettres, Université de Strasbourg, Arts et Métiers, INP Grenoble, INP ENSEEIHT, Ecole Normale Supérieure de Paris-Saclay, Université Grenoble-Alpes, Université Côte-d'Azur.
and, on the Singaporean side:
- 3 universities: Nanyang Technology University, National University of Singapore, Singapore University of Technology and Design.
- A*STAR: Agency for Science, Technology and Research. A*STAR is the national R&D agency of Singapore.
It is developed in collaboration with five industrial partners: ARIA, CETIM MATCOR, EDF, ESI Group and Thales.
About ESI Group
Founded in 1973, ESI Group is a leading innovator in Virtual Prototyping solutions and a global enabler of industrial transformation. Thanks to the company’s unique know-how in the physics of materials, it has developed and refined, over the last 45 years, advanced simulation capabilities. Having identified gaps in the traditional approach to Product Lifecycle Management (PLM), ESI has introduced a holistic methodology centered on industrial productivity and product performance throughout its entire lifecycle, i.e. Product Performance Lifecycle™, from engineering to manufacturing and in operation. Present in more than 20 countries, and in major industrial sectors, ESI employs 1200 high level specialists around the world and reported 2020 sales of €132.6 million. ESI is headquartered in France and is listed on compartment B of Euronext Paris.
For further information, go to www.esi-group.com.
Follow ESI: LinkedIn | Facebook | Twitter | YouTube
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220124005770/en/
Contact information
ESI - Press & Shareholders
Florence Barré
investors@esi-group.com
+33 1 49 78 28 28
Verbatee – Press & Investors Relations
Jérôme Goaer, j.goaer@verbatee.com, +33 6 61 61 79 34
Aline Besselièvre, a.besselievre@verbatee.com, +33 6 61 85 10 05
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 02:35:00 EEST | Press release
Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Capability of Next Generation Earth Observation Satellites Project Title: Source-Specific CO2 Emission and Uptake Monitoring through Satellite Constellation and Ai
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom